ID 264

Topic: CAR T cell therapies in hematological malignancies

ENGINEERING IMMUNOTHERAPY RESISTANT HEMATOPOIESIS TO TREAT HIGH-RISK ACUTE MYELOID LEUKEMIA

G. Casirati¹, A. Cosentino^1,2, L. Sereni¹, V. Cinella¹, A. Mucci¹, C. Brendel^1,3, A. Rambaldi², S. Armstrong^3,4, P. Genovese<sup>1,3

1</sup>Dana-Farber/Boston Children’s Cancer and Blood Disorder Center, Gene Therapy Program, Boston, United States of America
²ASST Papa Giovanni XXIII, Hematology And Bone Marrow Transplant Unit, Bergamo, Italy
³Harvard Medical School, Department Of Pediatrics, Boston, United States of America
⁴Dana-Farber/Boston Children’s Cancer and Blood Disorder Center, Pediatric Oncology, Boston, United States of America

ID 210

Topic: CAR and TCR targets

VEGF-A COMPETES WITH VEGFR-2-REDIRECTED CAR-T CELLS FOR TARGET BINDING AND IMPEDES FUNCTION

E. Lanitis¹, P. Kosti¹, C. Ronet¹, E. Cribioli¹, G. Rota¹, A. Spill¹, P. Reichenbach¹, V. Zoete², D. Dangaj Laniti¹, G. Coukos¹, M. Irving<sup>1

1</sup>Ludwig Center For Cancer Research, Lausanne University Hospital and University of Lausanne, Oncology, Epalinges, Switzerland
²Computer-aided Molecular Engineering Group,Ludwig Institute for Cancer Research, University of Lausanne, Oncology, Epalinges, Switzerland

ID 238

Topic: Engineered T cell therapy for solid tumours

UNICAR CAR T CELL THERANOTICS FOR DIAGNOSTIC IMAGING AND THERAPY OF PROSTATE CANCER

C. Arndt^1,2, R. Bergmann^1,3, F. Striese¹, D. Máthé³, N. Berndt¹, L. Loureiro¹, D. Szöllősi³, N. Kovács³, N. Hegedűs³, T. Kovács⁴, A. Feldmann¹, M. Bachmann^1,5,6,7

¹Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute Of Radiopharmaceutical Cancer Research, Dresden, Germany
²Mildred Scheel Early Career Center, TU Dresden, Faculty Of Medicine Carl Gustav Carus, Dresden, Germany
³Semmelweis University, Department Of Biophysics And Radiation Biology, Budapest, Hungary
⁴University of Pannonia, Institute Of Radiochemistry And Radioecology, Veszprem, Hungary
⁵National Center for Tumor Diseases (NCT), University Hospital ‘carl Gustav Carus’, Tu Dresden, Dresden, Germany
⁶German Cancer Consortium (DKTK), partner site Dresden, And German Cancer Research Center (dkfz), Heidelberg, Germany
⁷University Cancer Center (UCC) ‘Carl Gustav Carus’, Tumor Immunology, Tu Dresden, Dresden, Germany

ID 259

Topic: Engineered T cell therapy for solid tumours

EPITOPE SPREADING DRIVEN BY THE JOINT ACTION OF CAR T CELLS AND PHARMACOLOGICAL STING STIMULATION COUNTERACTS TARGET ANTIGEN ESCAPE

S. Hervas-Stubbs¹, E. Conde¹, E. Vercher¹, U. Mancheño¹, E. Elizalde¹, M.L. Rodriguez¹, N. Casares¹, M. Hommel¹, I. Uranga-Murillo², J. Pardo², I. Melero¹, J.J. Lasarte¹

¹Centro De Investigación Medica Aplicada, Immunology And Immunotherapy, Pamplona, Spain
²Biomedical Research Centre of Aragón (CIBA), Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Dpto. Microbiología Medicina Preventiva Y Salud Pública, Universidad De Zaragoza, Zaragoza, Spain

ID 248

Topic: Engineered T cell therapy for solid tumours

TARGETING THE EXTRA DOMAIN A FROM FIBRONECTIN FOR CANCER THERAPY WITH CAR-T CELLS

C. Martín-Otal¹, A. Lasarte-Cía¹, D. Serrano², N. Casares¹, F. Navarro¹, P. Sarrión¹, M. Gorraiz¹, C. De-Andrea³, J. Echeveste³, J.R. Rodriguez-Madoz⁴, J. San Miguel⁵, F. Prosper⁴, S. Hervás-Stubbs¹, J.J. Lasarte¹, T. Lozano¹

¹CIMA-Universidad de Navarra, Program Of Immunology And Immunotherapy, Pamplona, Spain
²CIMA, Solid Tumors, Pamplona, Spain
³Clínica Universidad de Navarra, Department Of Pathology, Pamplona, Spain
⁴CIMA, Hemato-oncology, Pamplona, Spain, ⁵Clínica Universidad de Navarra, Hematology, Pamplona, Spain

ID 192

Topic: Engineered T cell therapy for solid tumours

BOOSTING CAR T CELL EFFICACY BY MODULATION OF THE TUMOR MICROENVIRONMENT IN GLIOBLASTOMA

I. Mastandrea¹, D. Sher¹, D. Bayik², J. Lathia^2,3, D. Friedmann-Morvinski^1,4

¹Tel Aviv University, School Of Neurobiology, Biochemistry And Biophysics, The George S. Wise Faculty Of Life Sciences, Tel Aviv, Israel
²Lerner Research Institute, Cleveland Clinic, Cancer Impact Area And Department Of Cardiovascular & Metabolic Sciences, Cleveland, United States of America
³Cleveland Clinic, Rose Ella Burkhardt Brain Tumor And Neuro-oncology Center, Cleveland, United States of America
⁴Tel Aviv University, Sagol School Of Neurosciences, Tel Aviv, Israel

ID 255

Topic: Rare, autoimmune and infectious diseases as cell therapy targets

TACROLIMUS-RESISTANT SARS-COV-2-SPECIFIC T-CELL PRODUCTS TO PREVENT AND TREAT SEVERE COVID-19 IN IMMUNOSUPPRESSED PATIENTS

L. Peter¹, D. Wendering¹, S. Schlickeiser¹, H. Hoffmann², R. Noster¹, D. Wagner¹, G. Zarrinrad¹, S. Münch², S. Schulenberg¹, M.-F. Mashreghi³, P. Reinke², H.-D. Volk¹, L. Amini¹, M. Schmueck-Henneresse¹

¹Charité-Universitätsmedizin Berlin, B-crt, Berlin, Germany
²Charité – Universitätsmedizin Berlin, Becat, Berlin, Germany
³Deutsches Rheuma-Forschungszentrum Berlin, Therapeutic Gene Regulation, Berlin, Germany

ID 211

Topic: New approaches in lymphocyte engineering 

NANOPARTICLE-SENSITIZED PHOTOPORATION AS AN EMERGING NON-VIRAL ALTERNATIVE FOR T CELL ENGINEERING WITH NUCLEIC ACIDS

D. Berdecka¹, R. Xiong², A. Harizaj¹, G. Goetgeluk³, B. Vandekerckhove³, S. De Smedt¹, W. De Vos⁴, K. Braeckmans¹

¹Ghent University, Department Of Pharmaceutics, Ghent, Belgium
²Nanjing Forestry University, Joint Laboratory Of Advanced Biomedical Materials, Nanjing, China
³Ghent University, Department Of Diagnostic Sciences, Ghent, Belgium ⁴University of Antwerp, Department Of Veterinary Sciences, Antwerp, Belgium

ID 202

Topic: New approaches in lymphocyte engineering 

FUNCTIONAL CRISPR DISSECTION OF GENE NETWORKS CONTROLLING HUMAN REGULATORY T CELL IDENTITY

S. Raju¹, S. Kolb², A. Marson¹, K. Schumann<sup>2

1</sup>University of California, San Francisco, Department Of Microbiology And Immunology, San Francisco, United States of America
²Technical University of Munich, Institute For Medical Microbiology, Immunology And Hygiene, München, Germany

ID 234

Topic: New approaches in lymphocyte engineering 

ENGINEERING AVIDCARS FOR SMALL MOLECULE-DEPENDENT CAR T CELL REGULATION

B. Salzer¹, C. Schüller², C. Zajc³, M. Lehner^1,4, M. Traxlmayr<sup>3

1</sup>St. Anna Children’s Cancer Research Institute, Christian Doppler Laboratory For Next Generation Car T Cells, Vienna, Austria
²St. Anna Children´s Cancer Research Institute, Ccri, Vienna, Austria ³University of Natural Resources and Life Sciences, Christian Doppler Laboratory For Next Generation Car T Cells, Vienna, Austria
⁴Medical University of Vienna, Department Of Pediatrics, St. Anna Kinderspital, Vienna, Austria

ID 103

Topic: Other

A NOVEL TUMOR MODEL FOR THE STUDY OF CELLULAR IMMUNOTHERAPY USING HUMANIZED MICE

M. Kaulfuss¹, J. Mietz¹, C. Münz¹, O. Chijioke<sup>1,2

1</sup>University of Zurich, Institute Of Experimental Immunology, Zürich, Switzerland
²University Hospital Basel, Institute Of Pathology And Medical Genetics, Basel, Switzerland

ID 237

Topic: CAR T cell therapies in hematological malignancies

NOVEL STRATEGIES TO ENHANCE THE SAFETY OF CAR T-CELL IMMUNOTHERAPY: THE IMSAVAR PROJECT

M. Alb¹, H. Einsele¹, P. Loskill², A. Van Der Meer³, K. Sewald⁴, K. Reiche⁵, U. Köhl⁵, M. Hudecek<sup>1

1</sup>Universitätsklinikum Würzburg, Med. Klinik Und Poliklinik Ii, Würzburg, Germany
²Eberhard Karls University Tübingen, Dept. Of Women’s Health, Research Institute For Women’s Health, Tübingen, Germany
³University of Twente, Faculty Of Science And Technology, LW Enschede, Netherlands
⁴Fraunhofer-Institut, Toxikologie Und Experimentelle Medizin Item, Hannover, Germany
⁵Fraunhofer-Institut, Zelltherapie Und Immunologie Izi, Leipzig, Germany

ID 254

Topic: CAR T cell therapies in hematological malignancies

MECHANISMS OF RESISTANCE TO CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IN MULTIPLE MYELOMA

N. Camviel, B. Wolf, G. Croce, D. Gfeller, V. Zoete, C. Arber

Lausanne University Hospital, University of Lausanne, Switzerland and Ludwig institute for Cancer Research Lausanne Branch, Department Of Oncology Unil-chuv, Lausanne, Switzerland

ID 175

Topic: CAR T cell therapies in hematological malignancies

IMMUNE EFFECTOR CELLS TRANSDUCED WITH AN NKG2D CHIMERIC ANTIGEN RECEPTOR TO TREAT ACUTE MYELOID LEUKEMIA

L. Córdoba¹, E. Castellano¹, A. Valeri², A. Garcia-Ortiz¹, P. Río³, J. Encinas¹, E. Maroto¹, D. Lee⁴, D.J. Powell Jr.⁵, A. Leivas², J. Martínez-López²

¹Hospital Universitario 12 de Octubre, Translational Hematology, Madrid, Spain
²Fundación para la Investigación Biomédica H12O, H12o-cnio Hematological Malignancies Clinical Research Group, Ciberonc, Madrid, Spain
³CIEMAT, Erapias Innovadoras Hematopoyéticas, Madrid, Spain
⁴Nationwide Children’s Hospital, The Research Institute, Ohio, United States of America
⁵University of Pennsylvania, Department Of Pathology And Laboratory Medicine, Philadelphia, United States of America

ID 174

Topic: CAR T cell therapies in hematological malignancies

LOWERING THE BINDING STRENGTH OF ANTI-CD19 CAR-T CELLS CAN REDUCE TOXICITY BUT AT THE COST OF IN VIVO ANTI-TUMOR EFFICACY

S. Dötsch¹, L. Warmuth¹, E. D’Ippolito¹, B. Honold¹, M. Trebo¹, W. Manlik¹, F. Graml¹, A. Stengl², J. Schuetz¹, K. Schober^1,3, G. Schmidt⁴, A. Wanisch¹, M. Casucci⁵, S. Riddell⁶, D. Busch¹

¹Technical University of Munich, Institute For Medical Microbiology, Immunology And Hygiene, Munich, Germany
²LMU Munich, Biocenter, Planegg-Martinsried, Germany
³University Hospital of Erlangen, Clinical Microbiology, Erlangen, Germany
⁴University Hospital rechts der Isar of the Technical University of Munich, Department Of Gynecology And Obstetrics, Munich, Germany
⁵IRCCS San Raffaele Scientific Institute, 5innovative Immunotherapies Unit, Division Of Immunology, Transplantation And Infectious Diseases, Milan, Italy
⁶University of Washington, Fred Hutchinson Cancer Research Center, Seattle, United States of America

ID 219

Topic: CAR T cell therapies in hematological malignancies

NKG2D-CAR TCD45RA- CELLS BYPASS THE CANONIC TUMOR IMMUNOESCAPE MECHANISMS

A. Fernandez¹, M. Ibánez Navarro¹, A. Escudero², A. Navarro³, I. Mirones⁴, A. Ortiz⁵, P. Yagüe⁶, C. Campos-Silva⁷, G. Esteso⁷, C. Ferreras⁸, C. Rodriguez⁹, A. Leivas¹⁰, M. Vela¹¹, J. Martínez-López¹⁰, M. Valés⁷, A. Pérez-Martínez¹², L. Fernández<sup>1

1</sup>Spanish National Cancer Research Center – CNIO, Hematological Malignancies Laboratory Cnio-h12o, Clinical Research Unit, Madrid, Spain
²La Paz University Hospital, Pediatric Molecular Hemato-oncology Department, Medical And Molecular Genetics Institute (ingemm), Madrid, Spain
³La Paz University Hospital Institute for Health Research-IdiPAZ, Translational Research Group In Pediatric Oncology Hematopoietic Transplantation And Cell Therapy, Madrid, Spain
⁴La Paz University Hospital, Advanced Therapy Medicinal Products Production Unit, Pediatric Hemato-oncology Service And Pharmacy Service, Madrid, Spain
⁵Spanish National Cancer Centre (CNIO), Hematological Malignancies. Clinical Research Unit, Madrid, Spain
⁶Spanish National Cancer Center (CNIO), Lung Cancer. Clinical Research Unit, Madrid, Spain
⁷National Biotechnology Center, Tumor Immune Activation And Evasion Group, Madrid, Spain
⁸Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain, Translational Research In Paediatric Oncology, Haematopoietic Transplantation And Cell Therapy, Madrid, Spain
⁹La Paz University Hospital, Cancer Epigenetics Laboratory, Genetic Unit, Madrid, Spain
¹⁰Fundación para la Investigación Biomédica H12O, H12o-cnio Hematological Malignancies Clinical Research Group, Ciberonc, Madrid, Spain
¹¹Hospital La Paz Institute for Health Research-IdiPAZ, Biomarkers And Experimental Therapeutics In Cancer, Madrid, Spain
¹²University Hospital La Paz, Pediatric Hemato-oncology Department, Madrid, Spain

ID 144

Topic: CAR T cell therapies in hematological malignancies

CD33-DIRECTED IMMUNOTHERAPY WITH THIRD-GENERATION CHIMERIC ANTIGEN RECEPTOR T CELLS AND GEMTUZUMAB OZOGAMICIN IN INTACT AND CD33-EDITED ACUTE MYELOID LEUKEMIA AND HEMATOPOIETIC STEM AND PROGENITOR CELLS

Y. Liu

Heidelberg University Hospital, Medizinische Klinik V, Heidelberg, Germany

ID 157

Topic: CAR T cell therapies in hematological malignancies

BI-SPECIFIC LOGIC GATED CAR T CELLS ELIMINATING CD19+ TUMORS WHILE PREVENTING NEUROTOXICITY VIA PERICYTE-INDUCED INHIBITION

D. Martinez Bedoya¹, E. Marinari¹, O. Maxit¹, S. Momjian², V. Dutoit¹, D. Migliorini<sup>3

1</sup>Center for Translational Research in Onco Heamtology, University of GenevaUniversity of Geneva, Dpt. Of Oncology, Geneva, Switzerland
²University Hospital of Geneva, Dpt. Of Neurosurgery, Geneva, Switzerland
³University Hospital of Geneva, Dpt. Of Oncology, Geneva, Switzerland

ID 240

Topic: CAR T cell therapies in hematological malignancies

SITE-SPECIFIC IN VIVO T CELL ENGINEERING TO EXPRESS CHIMERIC ANTIGEN RECEPTORS

I. Reuveni¹, M. Horovitz-Fried¹, A. Nahmad², I. Dotan³, A. Barzel⁴

¹Tel Aviv University, Biochemistry, Petach-Tiqwa, Israel
²Tel Aviv Sourasky Medical Center, Dotan Center For Advanced Therapies, Tel Aviv, Israel
³Tel Aviv University, School Of Neurobiology, Biochemistry And Biophysics, Tel Aviv, Israel
⁴Tel-Aviv University, Israel, Biochemistry, Tel Aviv, Israel

ID 301

Topic: CAR T cell therapies in hematological malignancies

HOME BREWN 3G.CD19.CAR T CELLS FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – (HD-CAR-1)

M. Schmitt¹, P. Derigs¹, P. Dreger¹, A. Schmitt¹, M.-L. Schubert¹, A. Kunz¹, C. Müller-Tidow¹, M. Brüggemann², G. Kobbe³

¹Universitätsklinikum Heidelberg, Innere Medizin V, Heidelberg, Germany
²UKSH – Campus Kiel, Innere Med., Kiel, Germany
³Universitätsklinikum Düsseldorf, Hematology, Düsseldorf, Germany

ID 214

Topic: CAR T cell therapies in hematological malignancies

A CHIMERIC ANTIGEN RECEPTOR (CAR)-BASED CELLULAR SAFEGUARD MECHANISM FOR ADOPTIVE T CELL THERAPY

M. Svec¹, S. Dötsch¹, S. Fräßle¹, S. Riddell², E. D’Ippolito¹, D. Busch¹

¹TU Munich, Institute For Medical Microbiology, Immunology And Hygiene, München, Germany
²University of Washington, Fred Hutchinson Cancer Research Center, Seattle, United States of America

ID 204

Topic: CAR T cell therapies in hematological malignancies

A CONFORMATION-SPECIFIC ON-SWITCH FOR CONTROLLING CAR T CELLS WITH AN ORALLY AVAILABLE DRUG

E. Sylvander¹, C. Zajc², M. Dobersberger³, I. Schaffner⁴, B. Salzer¹, M. Traxlmayr², M. Lehner^1,5

¹St. Anna Children’s Cancer Research Institute, Christian Doppler Laboratory For Next Generation Car T Cells, Vienna, Austria
²University of Natural Resources and Life Sciences, Christian Doppler Laboratory For Next Generation Car T Cells, Vienna, Austria
³University of Natural Resources and Life Sciences, Vienna, Department Of Chemistry, Vienna, Austria
⁴University of Natural Resources and Life Sciences, Core Facility Biomolecular & Cellular Analysis, Vienna, Austria
⁵Medical University of Vienna, Department Of Pediatrics, St. Anna Kinderspital, Vienna, Austria

ID 253

Topic: CAR T cell therapies in hematological malignancies

MULTIPARAMETER CHARACTERIZATION OF CAR T CELLS

X. Wang¹, C. Pitzka¹, D. Rheindorf¹, J. Milleck¹, N. Mockel-Tenbrinck¹, T. Holzer¹, M. Essl¹, I. Bürger¹, M. Mues¹, A. Richter¹, T. Cathomen², C. Evaristo¹

¹Miltenyi Biotec B.V. & Co. KG, R&d, Bergisch Gladbach, Germany
²Medical Center – University of Freiburg, Institute For Transfusion Medicine And Gene Therapy, Freiburg im Breisgau, Germany

ID 292

Topic: CAR and TCR targets

CELL AVIDITY A KEY PARAMETER TO IMPROVE THE PREDICTABILITY OF T CELL FUNCTIONALITY FOR CELLULAR IMMUNOTHERAPIES

J. Ashby, Y. Bar-Ephraim, A. Candelli, K. Das, P. Djali, E. Fong, Y. Patankar, R. Reijmers, I. Sarkar, W. Singleterry, Z. Yu

LUMICKS C.A. B.V., Research And Development, Amsterdam, Netherlands

ID 203

Topic: CAR and TCR targets

STRATEGY TO INCREASE TUMOR SPECIFICITY OF EGFR-TARGETING THERAPIES

M. Dobersberger¹, E. Laurent², E. Sylvander³, J. Seigner¹, M. Teufl¹, B. Salzer³, C. Zajc¹, C. Obinger¹, M. Lehner^3,4, M. Traxlmayr¹

¹University of Natural Resources and Life Sciences, Department Of Chemistry, Vienna, Austria
²University of Natural Resources and Life Sciences, Boku Core Facility Biomolecular And Cellular Analysis, Vienna, Austria
³St. Anna Children’s Cancer Research Institute, Ccri, Vienna, Austria
⁴Medical University of Vienna, Department Of Pediatrics, St. Anna Kinderspital, Vienna, Austria

ID 125

Topic: CAR and TCR targets

GENERATING A NOVEL CAR-MACROPHAGE THERAPY FOR TREATMENT OF SOLID TUMORS

L. Farhat Younis

Tel Aviv university, Department Of Pathology, Sackler School Of Medicine, Tel Aviv, Israel

ID 115

Topic: CAR and TCR targets

HIGHLY EFFICIENT GENERATION OF TRANSGENICALLY AUGMENTED CAR NK CELLS OVEREXPRESSING CXCR4

A. Jamali¹, H.R. Mirzaei², J. Hadjati², E. Ullrich³, J. Hartmann⁴, Z. Madjd Jabbari⁵

¹Iran University of Medical Sciences, Molecular Medicine, Langen, Germany ²Tehran University of Medical Sciences, Immunilogy, Tehran, Iran
³Johanna Quandt Zentrum / Klinik der J. W. Goethe Universität, Experimentelle Immunologie, Pädiatrische Stammzelltransplantation & Immunologie, Frankfurt, Germany
⁴Paul Ehrlich Institute, Molecular Biotechnology And Genetherapy, Langen, Germany
⁵Iran University of Medical Sciences, Molecular Medicine, Tehran, Iran

ID 230

Topic: CAR and TCR targets

ENGINEERING AVIDCARS FOR COMBINATORIAL ANTIGEN RECOGNITION

M. Lehner¹, B. Salzer¹, C. Schüller¹, C. Zajc², M. Traxlmayr²

¹St. Anna Kinderkrebsforschung GmbH CHILDREN’S CANCER RESEARCH INSTITUTE / CCRI, Christian Doppler Laboratory For Next Generation Car T Cells, Vienna, Austria
²University of Natural Resources and Life Sciences, Christian Doppler Laboratory For Next Generation Car T Cells, Vienna, Austria

ID 304

Topic: CAR and TCR targets

PRODUCTION OF MONOCLONAL ANTIBODIES FOR THE T-CELL ENGINEERING AGAINST METASTATIC COLORECTAL CANCER

I. Marino, F. Guidi, P. Lanza, M. Paglialunga, E. Ponterio, S. Lucchisani, T. Haas, R. De Maria

Università Cattolica del Sacro Cuore, Department Of Translational Medicine And Surgery, Rome, Italy

ID 239

Topic: CAR and TCR targets

IDENTIFICATION OF HIGHLY FUNCTIONAL AND CYTOTOXIC SARS-COV-2-SPECIFIC CD8+ T CELLS BY ORTHOTOPIC TCR REPLACEMENT ENGINEERING

L. Mateyka¹, K. Wagner¹, S. Jarosch¹, V. Grass², S. Weber¹, M. Hammel¹, A. Pichlmair², C. Crowel¹, M. Gerhard¹, E. D’Ippolito¹, D. Busch¹

¹Technical University of Munich, Institute For Medical Microbiology, Immunology And Hygiene, Munich, Germany
²Technical University of Munich, Institute Of Virology, Munich, Germany

ID 297

Topic: CAR and TCR targets

NOVEL ANTIBODY TO REDIRECT T CELLS FOR CANCER IMMUNOTHERAPY IN COLORECTAL CANCER (CRC)

E. Ponterio¹, C. Valvo¹, G. Sette², C. Giudiceandrea¹, F. Guidi¹, M. Cappellari², L. Pasquini², A. Boe², P. Romania², E. Petrucci², E. Pilozzi³, C. Marchiò⁴, L. Ricci-Vitiani², M. Biffoni², T. Haas¹, R. De Maria¹

¹Università Cattolica del Sacro Cuore, Department Of Translational Medicine And Surgery, Rome, Italy
²Istituto Superiore di Sanità, Department Of Oncology And Molecular Medicine, Rome, Italy
³Sant’Andrea Hospital, University ‘La Sapienza’, Department Of Experimental Medicine, Rome, Italy
⁴Candiolo Cancer Institute, FPO-IRCCS Candiolo, Department Of Medical Sciences, Candiolo, Italy

ID 236

Topic: CAR and TCR targets

ULTRAHIGH-CONTENT IMAGING HELPS TO IDENTIFY CAR TARGET CANDIDATES AGAINST PANCREATIC ADENOCARCINOMA

D. Schäfer¹, S. Rösch²

¹Miltenyi Biotec B.V. & Co. KG, Research And Development, Köln, Germany
²Miltenyi Biotec, R&d, Bergisch Gladbach, Germany

ID 194

Topic: CAR and TCR targets

DISCOVERING AND ASSESSING TRANSCRIPTOMIC SIGNATURES OF ANTIGEN-DEPENDENT ACTIVATION IN NEOANTIGEN-SPECIFIC TCRS ON A SINGLE-CELL LEVEL

J. Untch¹, E. Bräunlein¹, F. Füchsl¹, S. Jarosch², N. De Andrade Krätzig^3,4, O. Baranov^3,4, T. Engleitner^3,4, D. Busch², R. Rad^3,4, A. Krackhardt^1,4,5

¹Technical University of Munich, Klinik Und Poliklinik Für Innere Medizin Iii, Munich, Germany
²Technical University of Munich, Institute For Medical Microbiology, Immunology And Hygiene, Munich, Germany
³Technical University of Munich, Institute Of Molecular Oncology And Functional Genomics, Munich, Germany
⁴Technical University of Munich, Center For Translational Cancer Research (translatum), Munich, Germany
⁵German Cancer Consortium (DKTK), partner-site Munich, And German Cancer Research Center (dkfz), Heidelberg, Germany

ID 289

Topic: CAR and TCR targets

HARNESSING CD70-DIRECTED CAR NATURAL KILLER CELLS WITH IL-15 IS NECESSARY TO ERADICATE SOLID TUMOUR CELLS AND CANCER-ASSOCIATED FIBROBLASTS

A. Van Den Eynde¹, J. Van Audenaerde¹, J. De Waele¹, T. Flieswasser¹, L. Gehrcken¹, H.W. Lau¹, C. Merlin¹, G. Roex², D. Campillo-Davo², J. Jacobs³, M. Peeters¹, F. Lardon¹, E. Smits¹, P. Pauwels¹

¹University of Antwerp, Center For Oncological Research (core), Integrated Personalized And Precision Oncology Network (ippon), Wilrijk, Belgium
²University of Antwerp, Vaxinfectio, Wilrijk, Belgium
³University of Antwerp, Center For Oncological Research (core), Integrated Personalized And Precision Oncology Network (ippon), Current Position At Argenx, Wilrijk, Belgium

ID 171

Topic: Engineered T cell therapy for solid tumours

SHED L1CAM IMPAIRS L1CAM-DIRECTED CAR T CELLS AGAINST NEUROBLASTOMA

L. Andersch¹, S. Schwiebert¹, A. Klaus¹, A. Winkler¹, A. Eggert^1,2,3, A. Künkele^1,2,3, K. Anders^1,3

¹Charité-Universitätsmedizin Berlin, Pediatric Oncology And Hematology, Berlin, Germany
²Berlin Institut of Health, Bih, Berlin, Germany
³German Cancer Consortium, Dktk, Heidelberg, Germany

ID 161

Topic: Engineered T cell therapy for solid tumours

TCR-QR: IDENTIFYING TUMOUR-REACTIVE TCRS FOR PERSONALIZED T CELL THERAPIES

F. Bieberich, R. Vazquez-Lombardi, S. Reddy

ETH Zurich, Bsse, Basel, Switzerland

ID 173

Topic: Engineered T cell therapy for solid tumours

NOVEL STRATEGIES FOR CAR T-CELL IMMUNOTHERAPY AGAINST GLIOBLASTOMA BASED ON MULTI-TARGETING AND MODULATION OF THE TUMOR MICROENVIRONMENT

A. Brosque¹, L. Russo-Noori¹, D. Tarab², A. Gutkin², D. Peer², D. Friedmann-Morvinski^1,3

¹Tel Aviv University, School Of Neurobiology, Biochemistry & Biophysics. George S. Wise Faculty Of Life Sciences, Tel Aviv, Israel
²Tel Aviv University, Dept. Of Cell Research & Immunology And Center For Nanoscience And Nanotechnology. George S. Wise Faculty Of Life Sciences, Tel Aviv, Israel
³Tel Aviv University, Sagol School Of Neurosciences, Tel Aviv, Israel

ID 305

Topic: Engineered T cell therapy for solid tumours

PROSTATE-CONFINED RADIOTHERAPY SUPPORTS TCR-REDIRECTED T CELLS TUMOR SEEDING INSTRUCTING LONG-LASTING PROTECTIVE IMMUNITY AGAINST THE PRIMARY TUMOR AND LIVER METASTASIS.

M. Catucci¹, V. Basso², C. Deantoni³, S. Baroni³, A. Spinelli⁴, M. Freschi⁵, C. Cozzarini³, C. Fiorino³, S. Formenti⁶, S. Demaria⁶, N. Di Muzio³, A. Mondino²

¹Via Olgettina 58, Division Of Immunology, Transplantation And Infectious Diseases, Milano, Italy
²IRCCS San Raffaele Scientific Institute, Division Of Immunology, Transplantation And Infectious Diseases, Milano, Italy
³IRCCS San Raffaele Scientific Institute, Radiation Oncology Department, Milano, Italy
⁴IRCCS San Raffaele Scientific Institute, Preclinical Imaging Facility, Milano, Italy
⁵IRCCS San Raffaele Scientific Institute, Pathology Department, Milano, Italy
⁶Weill Cornell Medicine, Department Of Radiation Oncology, New York, United States of America

ID 233

Topic: Engineered T cell therapy for solid tumours

A HIGH-THROUGHPUT WORKFLOW FOR THE FUNCTIONAL SCREENING AND CHARACTERIZATION OF CLINICALLY RELEVANT MHC CLASS I-RESTRICTED T CELL RECEPTORS FOR ADOPTIVE T CELL THERAPY

E. D’Ippolito¹, S. Scheu¹, K. Wagner¹, A. Kazeroonian¹, A. Hochholzer¹, F. Graml¹, N. Hamed¹, M. Hammel¹, I. Andrä¹, C. Moosmann², E. Boga¹, A.-K. Triebert¹, M. Dalenberg³, Y. Bar-Ephraim³, D. Busch¹

¹TU München, Institut Für Medizinische Mikrobiologie, Immunologie Und Hygiene, Munich, Germany
²University Hospital Erlangen, Institute Of Clinical Microbiology, Immunology And Hygiene, Erlangen, Germany
³LUMICKS C.A. B.V., Research And Development, Amsterdam, Netherlands

ID 303

Topic: Engineered T cell therapy for solid tumours

OPTIMIZATION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL TO IMPROVE SOLID TUMORS TREATMENT

C. Giudiceandrea¹, E. Ponterio¹, C. Valvo², G. Sette³, E. Coratella², T. Haas², R. De Maria²

¹Università Cattolica del Sacro Cuore, Department Of Translational Medicine And Surgery, rome, Italy
²Università Cattolica del Sacro Cuore, Department Of Translational Medicine And Surgery, Rome, Italy
³Istituto Superiore di Sanità, Department Of Oncology And Molecular Medicine, Rome, Italy

ID 224

Topic: Engineered T cell therapy for solid tumours

CHIMERIC ANTIGEN RECEPTOR-T CELLS DERIVED EXTRACELLULAR VESICLES AS A POTENTIAL CANCER THERAPY

G. Horn¹, A. Aharon², T. Hana Bar-Lev², E. Zagagi Yohay², T. Waks¹, M. Levin², N. Deshet Unger¹, I. Avivi², A. Globerson Levin<sup>1

1</sup>Ichilov Tel Aviv Medical Center, Immunotherapy Lab, Tel Aviv, Israel
²Ichilov Tel Aviv Medical Center, Hematology Lab, Tel Aviv, Israel

ID 193

Topic: Engineered T cell therapy for solid tumours

PHARMACOLOGICALLY INHIBITING MYCN IMPROVES L1CAM-DIRECTED CAR T CELL EFFICACY AGAINST MYCN-AMPLIFIED NEUROBLASTOMA

L. Grunewald¹, K. Anders^1,2, A. Künkele^1,2,3

¹Charité – Universitätsmedizin Berlin, Pediatric Oncology And Hematology, Berlin, Germany
²German Cancer Consortium DKTK, Dktk, Heidelberg, Germany
³Berlin Institute of Health (BIH), Berlin Institute Of Health, Berlin, Germany

ID 216

Topic: Engineered T cell therapy for solid tumours

CAR-T CELLS AND EXO-CAR T CELLS AS NOVEL TREATMENT FOR PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANT TUMORS

M. Ibánez Navarro¹, A. Fernandez¹, S. García-Silva², L. Clares-Villa³, C. Ferreras³, H. Peinado², A. Pérez-Martínez⁴, L. Fernández¹

¹Spanish National Cancer Research Center – CNIO, Hematological Malignancies Laboratory Cnio-h12o, Clinical Research Unit, Madrid, Spain
²Spanish National Cancer Research Center – CNIO, Microenvironment And Metastasis Laboratory, Department Of Molecular Oncology, Madrid, Spain
³Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain, Translational Research In Paediatric Oncology, Haematopoietic Transplantation And Cell Therapy, Madrid, Spain
⁴University Hospital La Paz, Pediatric Hemato-oncology Department, Madrid, Spain

ID 262

Topic: Engineered T cell therapy for solid tumours

EVOLVING MULTIPLEXED SHRNA TO GENERATE TAILORED CAR T CELL THERAPY

E. Breman, M. Steklov, B. Le Calve, H. Iserentant, D. Gilham

Celyad Oncology, R&d, Mont-Saint-Guibert, Belgium

ID 153

Topic: Engineered T cell therapy for solid tumours

CD137 AS A TARGET FOR TUMOR IMMUNOTHERAPY BY CHIMERIC ANTIGEN RECEPTORS

M. Prasad, Q. Zeng, H. Schwarz

National University of Singapore, Physiology, Singapore, Singapore

ID 291

Topic: Engineered T cell therapy for solid tumours

SYNTHETIC PROMOTERS TO INDUCE IMMUNE-EFFECTORS IN THE TUMOR MICROENVIRONMENT

O. Sharabi, Y. Greenshpan, A. Porgador, R. Gazit

Ben-Gurion University of the Negev, Department Of Microbiology, Immunology And Genetics, Faculty Of Health Sciences, Ben-gurion University Of The Negev, Beer Sheba, Israel

ID 188

Topic: Engineered T cell therapy for solid tumours

TARGETING SNX9 RESCUES CD28-MEDIATED T CELL EXHAUSTION FOR CANCER IMMUNOTHERAPY

M. Trefny¹, N. Kirchhammer¹, P. Auf Der Maur², M. Natoli¹, J. Lötscher², D. Schmid², P. Herzig², M. Akramisomeabozorg², M. Germann², J. Stinchcombe³, L. Fernandez Rodriguez², M. Stanczak¹, D. Thommen⁴, H. Läubli¹, B.-A. Mohamed¹, G. Griffiths³, C. Hess¹, Z. Alfred¹

¹University of Basel, Department Of Biomedicine, Basel, Switzerland
²University of Basel, Department Of Biomedicine, Hebelstrasse, Switzerland
³Addenbrooke’s Hospital, Cambridge Institute For Medical Research, Cambridge, Switzerland
⁴The Netherlands Cancer Institute, 7division Of Immunology, Amsterdam, Netherlands

ID 212

Topic: Engineered T cell therapy for solid tumours

ISOLATION AND CHARACTERIZATION OF RNF43 NEO-EPITOPE SPECIFIC TCRS FOR T CELL THERAPY IN GASTROINTESTINAL CANCER

K. Wagner, E. D’Ippolito, A. Brutau-Abia, A. Albert, R. Sonntag, R. Mejias-Luque, M. Gerhard, D. Busch

TU München, Institut Für Medizinische Mikrobiologie, Immunologie Und Hygiene, Munich, Germany

ID 155

Topic: Engineered T cell therapy for solid tumours

SENSING OF SOLUBLE ANTIGENS WITH ADAPTER CAR™ T CELLS

N. Werchau, K. Teppert, B. Kotter, P. Abramowski, A. Kaiser, T. Schaser

Miltenyi Biotec B.V. & CO. KG, R&d, Bergisch Gladbach, Germany

ID 287

Topic: Engineered T cell therapy for solid tumours

SIALYL-THOMSEN-NOUVEAU DIRECTED CAR-T CELLS TARGETING SOLID TUMORS

A. Zingg, H. Läubli

University of Basel, Department Of Biomedicine, Basel, Switzerland

ID 294

Topic: Non-viral vectors and transposons

GENETIC MODIFICATION OF T-CELLS FOR ADOPTIVE CELL THERAPIES USING NON-VIRAL S/MAR DNA VECTORS

A. De Roia^1,2,3,4, M. Bozza¹, A. Roig-Merino⁵, E. Green², R. Harbottle¹, M. Platten^2,4,6

¹German Cancer Research Center (DKFZ), Dna Vector Laboratory, Heidelberg, Germany
²German Cancer Research Center (DKFZ), Dktk (german Cancer Consortium) Clinical Cooperation Unit (ccu) Neuroimmunology And Brain Tumor Immunology, Heidelberg, Germany
³Heidelberg University, Faculty Of Biosciences, Heidelberg, Germany
⁴Medical Faculty Mannheim, Heidelberg University, Department Of Neurology, Mannheim, Germany
⁵MaxCyte, R&d, Gaithersburg, United States of America
⁶National Center for Tumor Diseases (NCT), Immune Monitoring Unit, Heidelberg, Germany

ID 205

Topic: Non-viral vectors and transposons

AN OPTIMIZED FULLY RNA-BASED PLATFORM FOR CRISPR/CAS9-MEDIATED DISRUPTION OF NATIVE T-CELL RECEPTORS FOR T-CELL THERAPIES

D. Flumens¹, K. Luyckx¹, I. Janssens², D. Campillo-Davo¹, E. Lion¹

¹University of Antwerp, Vaxinfectio, Wilrijk, Belgium
²University of Antwerp, Faculty Of Medicine And Health Sciences, Antwerp, Belgium

ID 137

Topic: Non-viral vectors and transposons

ORTHOTOPIC T CELL RECEPTOR REPLACEMENT – NEXT-GENERATION ENGINEERING OF T CELLS FOR THERAPY

K. Schober

University Hospital of Erlangen, Clinical Microbiology, Erlangen, Germany

ID 261

Topic: Allogeneic/universal donor cells

NOVEL CRISPR/CAS9-BASED ALLOGENEIC CAR-T CELLS TARGETING NKG2D LIGANDS: A POTENTIAL UNIVERSAL CELL THERAPY AGAINST CANCER

C. Aparicio¹, M. Belver¹, F. Espeso¹, L. Enríquez¹, J. Serna Pérez¹, A. Valeri², A. Leivas², D.J. Powell Jr.³, J. García-Sancho¹, J. Martínez-López², A. Sánchez¹, M.Á. De La Fuente¹, M. González-Vallinas<sup>1

1</sup>University of Valladolid (UVa)-CSIC, Institute Of Biology And Molecular Genetics (ibgm), Valladolid, Spain
²H12O-CNIO Hematological Malignancies Clinical Research Group, CIBERONC, Fundación Para La Investigación Biomédica H12o, Madrid, Spain
³University of Pennsylvania, Department Of Pathology And Laboratory Medicine, Philadelphia, United States of America

ID 100

Topic: Allogeneic/universal donor cells

ANTIGEN-SPECIFIC REDIRECTION OF OFF-THE-SHELF NK-92 CELLS USING THE UNIVERSAL CAR PLATFORM ‘‘UNICAR’’

N. Mitwasi¹, A. Feldmann¹, C. Arndt¹, S. Koristka¹, N. Berndt¹, L. Loureiro¹, R. Bergmann^1,2, C. Rössig³, T. Tonn^4,5, W. Wels^6,7,8, M. Bachmann^1,5,9,10

¹Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute Of Radiopharmaceutical Cancer Research, Dresden, Germany
²Semmelweis University, Department Of Biophysics And Radiation Biology, Budapest, Hungary
³University Children´s Hospital Münster, Department Of Pediatric Hematology And Oncology, Münster, Germany
⁴Expermintal Transfusion Medicine, Medical Faculty ‘carl Gustav Carus’, Tu Dresden, Dresden, Germany
⁵German Cancer Consortium (DKTK), partner site Dresden, And German Cancer Research Center (dkfz), Heidelberg, Germany
⁶Georg-Speyer-Haus, Institute For Tumor Biology And Experimental Therapy, Frankfurt am Main, Germany
⁷German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, And German Cancer Research Center (dkfz), Heidelberg, Germany
⁸Frankfurt Cancer Institute, Goethe University, Frankfurt am Main, Germany
⁹National Center for Tumor Diseases (NCT), University Hospital ‘carl Gustav Carus’, Tu Dresden, Dresden, Germany
¹⁰University Cancer Center (UCC) ‘Carl Gustav Carus’, Tumor Immunology, Tu Dresden, Dresden, Germany

ID 245

Topic: Allogeneic/universal donor cells

CD33-TARGETING PRIMARY CAR-NK CELLS DISPLAY POTENT ANTITUMOUR ACTIVITY AGAINST ACUTE MYELOID LEUKAEMIA

M. Quadflieg¹, N. Albinger^2,3,4, M. Nitsche¹, R. Pfeifer¹, C. Zhang¹, E. Ullrich^2,3,4, N. Möker¹

¹Miltenyi Biotec B.V. & Co. KG, R&d Reagents, Bergisch Gladbach, Germany
²Childrens Hospital, Experimental Immunology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
³German Cancer Consortium (DKTK), Partner Site Frankfurt/mainz, Frankfurt am Main, Germany
⁴Frankfurt Cancer Institute, Johann Wolfgang Goethe University, Frankfurt am Main, Germany

ID 247

Topic: Allogeneic/universal donor cells

DEVELOPMENT OF AN OFF-THE-SHELF BCMA/CD19 CAR-NK CELL THERAPY FOR B CELL MALIGNANCIES

G. Roex, D. Campillo-Davo, H. De Reu, Z. Berneman, E. Lion, S. Anguille

University of Antwerp, Vaxinfectio, Wilrijk, Belgium

ID 235

Topic: Rare, autoimmune and infectious diseases as cell therapy targets

DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDES FOR IMMUNOMODULATION

V. Iyer^1,2, A.T. Phan², F. Wermeling¹

¹Karolinska Sjukhuset, Solna, Centrum för Molekylär Medicin, Enheten För Reumatologi, Stockholm, Sweden
²Nanyang Technological University, School Of Physical And Mathematical Sciences, Singapore, Singapore

ID 198

Topic: Rare, autoimmune and infectious diseases as cell therapy targets

ENGINEERING OF REGULATORY T CELLS BY MEANS OF MRNA ELECTROPORATION IN A GMP-COMPLIANT MANNER

I. Janssens, D. Campillo-Davo, J. Van Den Bos, H. De Reu, Z. Berneman, I. Wens, N. Cools

University of Antwerp, Faculty Of Medicine And Health Sciences, Antwerp, Belgium

ID 232

Topic: Rare, autoimmune and infectious diseases as cell therapy targets

ENGINEERING HUMAN CD4 LYMPHOCYTES WITH RESISTANCE TO HIV-1 VIA MT-C34 PEPTIDE KNOCK-IN INTO CXCR4 LOCUS

D. Komkov¹, N. Kruglova¹, A. Maslennikova², D. Mazurov¹

¹Institute of Gene Biology Russian Academy of Sciences, Center For Precision Genome Editing And Genetic Technologies For Biomedicine, Moscow, Russian Federation
²Institute of Gene Biology Russian Academy of Sciences, Cell And Gene Technology Group, Moscow, Russian Federation

ID 281

Topic: Rare, autoimmune and infectious diseases as cell therapy targets

CHIMERIC AUTOANTIBODY RECEPTOR T CELLS TARGETING AUTOREACTIVE B CELLS IN N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ENCEPHALITIS

S.M. Reincke^1,2, M.A. Homeyer^1,2, N. Von Wardenburg^1,2, H.-C. Kornau³, D. Schmitz³, I. Edes⁴, H. Prüss<sup>1,2

1</sup>Charité Universitätsmedizin, Neurology, Berlin, Germany
²Deutsches Zentrum für Neurodegenerative Erkrankungen, Autoimmune Encephalopathies, Berlin, Germany
³Deutsches Zentrum für Neurodegenerative Erkrankungen, Network Dysfunction, Berlin, Germany
⁴MDC Berlin, Captain T Cell, Berlin, Germany

ID 295

Topic: Rare, autoimmune and infectious diseases as cell therapy targets

MHC CLASS II-RESTRICTED T-CELL-RECEPTORS PROVIDE HELP FOR T-CELL-THERAPY OF HEPATITIS B VIRUS INFECTION

S. Schreiber¹, J. Wettengel^1,2, K. Krey¹, K. Wisskirchen^1,2, U. Protzer^1,2

¹Technical University of Munich / Helmholtz Zentrum München, Institute Of Virology, München, Germany
²German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany

ID 307

Topic: Rare, autoimmune and infectious diseases as cell therapy targets

CHIMERIC AUTOANTIBODY RECEPTOR (CAAR) T CELLS AS INNOVATIVE TREATMENT OF ACHR ANTIBODY POSITIVE MYASTHENIA GRAVIS

N. Von Wardenburg^1,2, S.M. Reincke^1,2, M.A. Homeyer^1,2, S. Bandura², N. Lelievre², A. Pelz¹, A. Meisel¹, H. Prüss^1,2

¹Charité Universitätsmedizin, Neurology, Berlin, Germany
²Deutsches Zentrum für Neurodegenerative Erkrankungen, Autoimmune Encephalopathies, Berlin, Germany

ID 266

Topic: New approaches in lymphocyte engineering 

NUCLEASE-FREE ENGINEERING OF B-CELLS AGAINST HIV

T. Akriv, A. Nahmad, D. Nataf, I. Dotan, A. Barzel

Tel Aviv University, School Of Neurobiology, Biochemistry And Biophysics, Tel Aviv, Israel

ID 187

Topic: New approaches in lymphocyte engineering 

ENGINEERED ADENOVIRAL VECTORS EFFICIENTLY TRANSDUCE PRIMARY MURINE LYMPHOCYTES IN VITRO AND IN VIVO

P. Boucher¹, S. Mendonca², D. Curiel²

¹Washington University in St. Louis, Biomedical Engineering, St. Louis, United States of America
²Washington University in St. Louis, Radiation Oncology, St. Louis, United States of America

ID 201

Topic: New approaches in lymphocyte engineering 

DASATINIB ENHANCES GENE DELIVERY BY T CELL-TARGETED LENTIVIRAL VECTORS THROUGH CD3 UPREGULATION

A. Braun¹, A. Frank², C. Buchholz¹

¹Paul-Ehrlich-Institut, Molecular Biotechnology And Gene Therapy, Langen, Germany
²Paul-Ehrlich-Institut, Medical Biotechnology, Langen, Germany

ID 195

Topic: New approaches in lymphocyte engineering 

SPEEDINGCARS: ACCELERATING THE ENGINEERING OF CAR T CELLS BY SIGNALING DOMAIN SHUFFLING AND SINGLE-CELL SEQUENCING

R. Castellanos-Rueda¹, R. Di Roberto¹, F. Schlatter¹, D. Palianina², O. Nguyen¹, E. Kapetanovic¹, A. Hierlemann¹, N. Khanna², S. Reddy¹

¹ETH Zurich, Bsse, Basel, Switzerland
²University of Basel, Department Of Biomedicine, Basel, Switzerland

ID 162

Topic: New approaches in lymphocyte engineering

MONITORING EARLY TRANSCRIPTIONAL PROFILES OF CAR T CELL PRODUCTS GENERATED WITH CONVENTIONAL OR CD8-TARGETED LENTIVIRAL VECTORS

F. Charitidis¹, E. Adabi¹, F. Thalheimer², C. Miskey³, L. Childs³, C. Clarke⁴, C. Buchholz⁵

¹Paul-Ehlrich-Institut, Molecular Biotechnology And Gene Therapy, Langen, Germany
²Paul-Ehrlich-Institut, Molecular Biotechnology And Gene Therapy, Langen, Germany
³Paul-Ehrlich-Institut, Medical Biotechnology, Langen, Germany
⁴National Institute for Bioprocessing Research and Training, Systems Biology Research Group, Co. Dublin, Ireland
⁵Paul Ehrlich Institut, Molecular Biotechnology And Gene Therapy, Langen, Germany

ID 282

Topic: New approaches in lymphocyte engineering 

EX VIVO GENERATED THYMIC NK CELLS AS A POTENTIAL CELLULAR THERAPY IN NEUROBLASTOMA

A. Cornel^1,2, D. Petcu¹, E. Dunnebach^1,2, V. Lo Presti^1,2, C. De Koning^1,2, M. Van Dierselhuis², S. Nierkens^1,2

¹UMC Utrecht, Center For Translational Immunology, Utrecht, Netherlands
²Princess Máxima Center, Research, Utrecht, Netherlands

ID 151

Topic: New approaches in lymphocyte engineering 

CHARACTERIZATION AND MODULATION OF ANTI-ΑΒTCR ANTIBODIES AND THEIR RESPECTIVE BINDING SITES AT THE ΒTCR CHAIN TO ENRICH ENGINEERED T CELLS

G.J.J. Kierkels¹, E. Van Diest², P. Hernández-López², W. Scheper¹, A.C.M. De Bruin², E. Frijlink², T. Aarts-Riemens¹, S. Van Dooremalen², D.X. Beringer¹, R. Oostvogels³, L. Kramer¹, T. Straetemans¹, W. Uckert⁴, Z. Sebestyén¹, J.H.E. Kuball<sup>1,3

1</sup>UMC Utrecht, Center For Translational Immunology (cti), Utrecht, Netherlands
²UMC Utrecht, Center For Translational Immunology, Utrecht, Netherlands
³University Medical Center Utrecht, Department Of Hematology, Utrecht, Netherlands
⁴Max-Delbrück-Centrum für Molekulare Medizin (MDC), -, Berlin, Germany

ID 172

Topic: New approaches in lymphocyte engineering 

PHOTOPORATION OF NK92 CELLS WITH BIODEGRADABLE POLYDOPAMINE NANOSENSITIZERS AS A PROMISING STRATEGY FOR THE GENERATION OF CAR-NK CELL THERAPIES.

C. Hinnekens¹, A. Harizaj¹, I. Goemaere¹, D. Berdecka¹, S. De Smedt¹, B. Vandekerckhove², J. Fraire¹, K. Braeckmans¹

¹UGent, Laboratory Of General Biochemistry En Physical Pharmacy, Ghent, Belgium
²Ghent University, Department Of Diagnostic Sciences, Ghent, Belgium

ID 285

Topic: New approaches in lymphocyte engineering 

TRANSIENT EXPRESSION OF A CD123-DIRECTED CHIMERIC ANTIGEN RECEPTOR FOR SAFE IMMUNOTHERAPY OF ACUTE MYELOID LEUKEMIA

R. Kitte¹, S. Fricke¹, U. Köhl², S. Tretbar¹

¹Fraunhofer Institute for Cell Therapy and Immunology, Department Of Gmp Process Development And Atmp Design, Leipzig, Germany
²Fraunhofer-Institut, Zelltherapie Und Immunologie Izi, Leipzig, Germany

ID 142

Topic: New approaches in lymphocyte engineering 

P329G-CAR-T: A NOVEL ADAPTOR CAR-T CELL PLATFORM RECOGNIZING THE P329G MUTATION IN THERAPEUTIC IGG1 ANTIBODIES FOR ADOPTIVE T CELL THERAPY APPLICATIONS

D. Darowski¹, M.-R. Benmebarek², C. Jost¹, K. Stubenrauch³, U. Wessels³, J. Benz⁴, A. Freimoser-Grundschober¹, E. Moessner¹, R. Myburgh⁵, P. Umana¹, S. Kobold², C. Klein<sup>1

1</sup>Roche Glycart AG, Roche Innovation Center Zurich, Schlieren, Switzerland
²Klinikum der Universität München, Division Of Clinical Pharmacology, Munich, Germany
³Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany
⁴Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland
⁵University Hospital Zurich, Experimental Hematology Lab, Zurich, Switzerland

ID 207

Topic: New approaches in lymphocyte engineering 

SATB1 AND HIVEP2 CO-REGULATE HUMAN TREG CELL IDENTITY AND FUNCTION

S. Kolb¹, J. Müschen¹, C. Schmidl², K. Schumann¹

¹Technical University of Munich, Institute For Medical Microbiology, Immunology And Hygiene, Munich, Germany
²University Hospital Regensburg, Rci Regensburg Center For Interventional Immunology, Regensburg, Germany

ID 93

Topic: New approaches in lymphocyte engineering 

CRISPR-ENGINEERED GAUCHER’S MODEL PROVIDES A POWERFUL TOOL TO EVALUATE THE SAFETY AND EFFICACY OF PROTEIN REPLACEMENT THERAPY AND NANOMEDICINE

A. Brown, B. Lawler, J. Zhang, B. Lu

Santa Clara University, Department Of Bioengineering, Santa Clara, United States of America

ID 166

Topic: New approaches in lymphocyte engineering 

TREATMENT OF GAUCHER DISEASE USING BETA-GLUCOCEREBROSIDASE-LOADED EXOSOMES

B. Lu¹, A. Brown²

¹Santa Clara University, Department Of Bioengineering, Santa Clara, United States of America
²Santa Clara University, Department Of Bioengineering, San Francisco, United States of America

ID 182

Topic: New approaches in lymphocyte engineering 

ACCELERATING DEVELOPMENT AND IMPROVING ACCESS TO CAR- AND TCR-ENGINEERED T CELL THERAPY IN EUROPE

M. Luu¹, C. Sanges¹, N. Hoen², A. Draper², S. Sheth², S. Wagers², H. Negre³, M. Hudecek¹

¹University Hospital Würzburg, Medicine Ii, Würzburg, Germany
²BioSci Consulting, Project Management, Maasmechelen, Belgium
³Servier, Biotechnology & Bioproduction, Suresnes, France

ID 184

Topic: New approaches in lymphocyte engineering 

MICROBIAL SHORT-CHAIN FATTY ACIDS ENHANCE CD8+ T CELL-MEDIATED CANCER IMMUNOTHERAPY

M. Luu¹, Z. Riester¹, S. Danhof¹, T. Nerreter¹, I. Mulder², A. Visekruna³, M. Hudecek¹

¹University Hospital Würzburg, Medicine Ii, Würzburg, Germany
²4D Pharma, Research And Development, Aberdeen, United Kingdom
³Philipps-University Marburg, Institute For Medical Microbiology And Hygiene, Marburg, Germany

ID 228

Topic: New approaches in lymphocyte engineering 

FLOW CYTOMETRIC ASSAYS FOR CAR T CELL MANUFACTURING AND PATIENT MONITORING, INVOLVING SPECIFIC CAR DETECTION REAGENTS, STABILIZED PRE-FORMULATED COCKTAILS, AND AUTOMATED DATA ACQUISITION AND ANALYSIS

Mues, S. Biedermann, M. Winkels, K. Lange, L. Stiem, E. Janz, M. Niemöller, D. Missing, N. Borgelt, A. Brauchle, T. Holzer, C. Dose, S. Rösch, C. Siewert, A. Richter

Miltenyi Biotec, Research&development, Bergisch Gladbach, Germany

ID 250

Topic: New approaches in lymphocyte engineering 

A NOVEL GENE-EDITED REGULATORY T CELL PRODUCT RESISTANT TO TACROLIMUS

G. Zarrinrad^1,2, D. Wendering¹, S. Schlickeiser^1,3, L. Peter^1,2, S. Schulenberg^1,2, S. Picht¹, D. Wagner^1,4, K. Ou¹, J. Polánsky-Biskup¹, M.-F. Mashreghi^1,5, H.-D. Volk^1,3,4, P. Reinke^1,4, M. Schmueck-Henneresse^1,4, L. Amini^1,4

¹Charité-Universitätsmedizin Berlin, B-crt, Berlin, Germany
²Charité-Universitätsmedizin Berlin, Ecrt, Berlin, Germany
³Charité-Universitätsmedizin Berlin, Institute Of Medical Immunology, Berlin, Germany
⁴Charité-Universitätsmedizin Berlin, Becat, Berlin, Germany
⁵Deutsches Rheuma-Forschungszentrum Berlin, Therapeutic Gene Regulation, Berlin, Germany

ID 263

Topic: Other

AUTOMATED AND SCALABLE CLOSED-SYSTEM PLATFORM FOR CAR-T CELL ISOLATION AND ACTIVATION

H. Meås¹, H. Almåsbak², I. Schrøder¹, K. Alfsnes¹, N. Nilssen¹, S. Mevatne¹, J. Rasmussen¹, K.S. Chong³, M.T. Sia³, S. Lim³, S.H. Dong³, W.L.T. Soh³, A. Wilbur⁴, R. Thompson⁴, D. Hernandez⁵, B. Boo³, J. Zhu³, H. Nyheim¹, J. Green³, I. Dillon⁶, E. Kang⁷, H. Vebø¹, T. Holt Hereng¹, Ø. Åmellem<sup>1

1</sup>ThermoFisher Scientific, Bio Production Group, OSLO, Norway
²Thermo Fisher Scientific, Cellular Medicine, Oslo, Norway
³ThermoFisher Scientific, Genetic Sciences Division, Singapore, Singapore
⁴ThermoFisher Scientific, Life Science Solution Group, Chelmsford, United States of America
⁵ThermoFisher Scientific, Life Science Solution Group, Carlsbad, United States of America
⁶ThermoFisher Scientific, Bio Production Group, Grand Island, United States of America
⁷ThermoFisher Scientific, Bio Production Group, Durham, United States of America

ID 213

Topic: Other

EARLY DIVERSIFICATION DURING CHRONIC INFECTION GENERATES EXHAUSTION-RECEPTIVE AND -RESISTANT T CELL SUBSETS

L. Kretschmer¹, A. Toska¹, T. Busch¹, I. Andrä¹, D. Zehn², M. Flossdorf¹, V. Buchholz<sup>1

1</sup>Technical University of Munich (TUM), Institute For Medical Microbiology, Immunology And Hygiene, Munich, Germany
²Technical University of Munich (TUM), Division Of Animal Physiology And Immunology, School Of Life Sciences Weihenstephan, Garching, Germany

ID 252

Topic: Other

DEVELOPING AND IMPROVING A NATURAL KILLER CELL BASED MODEL AGAINST MULTIPLE MYELOMA

D. Giraldos, C. Reina-Ortiz, N. Sancho-Camón, J. Naval, A. Anel

Immunity, Cancer and Stem Cells Group, University Of Zaragoza, Zaragoza, Spain

ID 244

Topic: Other

T CELL STEMNESS DURING CHRONIC INFECTION IS MAINTAINED BY ONLY A SUBCOMPARTMENT OF TCF1+ CELLS

L. Kretschmer¹, S. Rapelius¹, S. Jarosch¹, A. Mühlbauer¹, D. Zehn², V. Buchholz¹

¹Technical University of Munich (TUM), Institute For Medical Microbiology, Immunology And Hygiene, Munich, Germany
²Technical University of Munich (TUM), Division Of Animal Physiology And Immunology, Freising, Germany

ID 223

Topic: Other

NEOADJUVANT PD-1/PD-L1 INHIBITORS FOR RESECTABLE HEAD AND NECK CANCER

R. Masarwy

Tel-Aviv Sourasky Medical Center, Otolaryngology, Head And Neck And Maxillofacial Surgery, Tel Aviv, Israel

ID 218

Topic: Other

ENDOSOMAL SIGNALING OF ANTIGEN RECEPTORS

L. Saveanu

inserm, U1149, PARIS, France

ID 181

Topic: Other

HUMANISATION OF LARGER NSGS-MOUSE COHORTS FROM SINGLE CORD BLOOD DONOR MATERIAL FOR MORE STANDARDIZED IN VIVO TESTING OF ENGINEERED T CELLS

J. Schuetz¹, S. Dötsch¹, G. Schmidt², F. Mohr³, P. Winterhalter¹, L. Warmuth¹, J. Barton¹, E. D’Ippolito¹, D. Hutmacher^4,5, D. Busch^1,6

¹Technical University of Munich, Institute For Medical Microbiology, Immunology And Hygiene, Munich, Germany
²Klinikum rechts der Isar and Comprehensive Cancer Center (CCCTUM), Technical University of Munich, Department Of Gynecology And Obstetrics, Munich, Germany
³IBA GmbH, Cell Selection And Expansion, Goettingen, Germany
⁴Queensland University of Technology, Institute Of Health And Biomedical Innovation, Kelvin Grove, Australia
⁵Australian Research Council, Industrial Transformation Training Centre In Additive Biomanufacturing, Kelvin, Australia
⁶German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany

ID 242

Topic: Other

INFLUENCE OF CD19 DENSITY AND AFFINITY ON CAR T CELL ACTIVATION: A COMBINATORIAL ANALYSIS OF DIFFERENT PARAMETERS AND THEIR IMPACT ON CAR ACTIVITY

J. Seigner¹, E. Laurent², C. Zajc¹, B. Salzer³, C. Obinger¹, M. Lehner^3,4, M. Traxlmayr¹

¹University of Natural Resources and Life Sciences, Department Of Chemistry, Vienna, Austria
²University of Natural Resources and Life Sciences, Boku Core Facility Biomolecular And Cellular Analysis, Vienna, Austria
³St. Anna Children´s Cancer Research Institute, Ccri, Vienna, Austria
⁴Medical University of Vienna, Department Of Pediatrics, St. Anna Kinderspital, Vienna, Austria

ID 185

Topic: Other

DISSECTING THE INTERPLAY OF TCR AVIDITY OF NAIVE CD8+ T CELLS AND TCR RECRUITMENT AFTER ANTIGEN EXPOSURE BY ENGINEERING POLYCLONAL REPERTOIRES

A. Straub¹, S. Grassmann^1,2, S. Jarosch¹, T. Müller^1,3, K. Wagner¹, M. Hammel¹, V. Buchholz¹, K. Schober⁴, D. Busch¹

¹Technical University Munich, Institute For Medical Microbiology, Immunology And Hygiene, Munich, Germany
²Memorial Sloan Kettering Cancer Center, The Joseph Sun Lab, New York, United States of America
³Karolinska Institutet, Centrum För Infektionsmedicin, Stockholm, Sweden
⁴University Hospital of Erlangen, Clinical Microbiology, Erlangen, Germany

ID 243

Topic: Other

ASSESSMENT OF WNT/Β-CATENIN SIGNALING PATHWAY MODIFICATIONS IMPACT ON TH17 CELLS DIFFERENTIATION – IN VITRO STUDY ON COMPANION DOG MODEL

I. Szopa, M. Granica, R. Pingwara, K. Majchrzak-Kuligowska

Warsaw University of Life Sciences, Institute Of Veterinary Medicine, Department Of Physiological Sciences, Warsaw, Poland

ID 231

Topic: Other

POTENTIAL CORRELATION BETWEEN THERMOSTABILITIES OF ANTIGEN BINDING DOMAINS AND CAR EXPRESSION LEVELS

M. Teufl¹, F. Schubert¹, C. Zajc¹, B. Salzer², M. Lehner^2,3, M. Traxlmayr¹

¹University of Natural Resources and Life Sciences, Christian Doppler Laboratory For Next Generation Car T Cells, Vienna, Austria
²St. Anna Children’s Cancer Research Institute, Christian Doppler Laboratory For Next Generation Car T Cells, Vienna, Austria
³Medical University of Vienna, Department Of Pediatrics, St. Anna Kinderspital, Vienna, Austria

ID 306

Topic: Other

BRIDGING THE GAP – ATMP PROCESS DEVELOPMENT ACCELERATING FROM BENCH- TO BED-SIDE

S. Tretbar¹, U. Blache¹, A.-R. Blaudszun¹, A. Duenkel¹, P. Franz¹, D. Schmiedel¹, U. Köhl^2,3,4, S. Fricke¹

¹Fraunhofer Institute for Cell Therapy and Immunology, Department Of Gmp Process Development And Atmp Design, Leipzig, Germany
²Fraunhofer Institute for Cell Therapy and Immunology, Institute’s Director, Leipzig, Germany
³University of Leipzig, Institute For Clinical Immunology, Leipzig, Germany
⁴Hanover Medical School, Institute Of Cellular Therapeutics, Hanover, Germany